A Compassionate Access Protocol For Those Patients Who Have Completed A4001029
NCT00801515
Last updated date
ABOUT THIS STUDY
This is a compassionate study to provide continued access to maraviroc for only those
subjects completing study A4001029 who are showing clinical benefit. Assessments of safety
and tolerability of maraviroc when added to OBT will be continued.
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
HIV
Sex
Females and Males
Age
18 + years
Inclusion Criteria
Show details
- Patients having completed study A4001029 in Canada and still deriving clinical benefit.
Exclusion Criteria
Show details
- None
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
HIVEffects Of Food And Dose Regimen On The Antiviral Effects Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
NCT00634959
- Birmingham, Alabama
- Boston, Massachusetts
- Frankfurt,
- Hamburg,
- Koeln,
- London,
- London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIVA Compassionate Access Protocol For Those Patients Who Have Completed A4001029
NCT00801515
- Montreal, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIVMaraviroc Switch Collaborative Study
NCT01384682
- Buenos Aires, Ciudad de Buenos Aires
- Buenos Aires, Ciudad de Buenos Aires
- Buenos Aires, Ciudad de Buenos Aires
- El Palomar, Provincia de Buenos Aires
- Isidro Casanova, Provincia de Buenos Aires
- Rosario, Provincia de Santa Fe
- Buenos Aires,
- Cordoba,
- Sydney, New South Wales
- Sydney, New South Wales
- Sydney, New South Wales
- Sydney, New South Wales
- Bisbane, Queensland
- Brisbane, Queensland
- Nambour, Queensland
- Adelaide, South Australia
- Melbourne, Victoria
- Melbourne, Victoria
- Calgary, Alberta
- Toronto, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Santiago, Santiago RM
- Orleans,
- Frankfurt, Frankfurt am Main
- Berlin,
- Berlin,
- Bonn,
- Cologne,
- Düsseldorf,
- Hannover,
- Dublin,
- Nagoya,
- Guadalajara, Jalisco
- Leon,
- Mexico City,
- Warsaw,
- Badalona, Catalonia
- Barcelona, Catalonia
- Barcelona, Catalonia
- Madrid,
- Madrid,
- Malaga,
- Seville,
- Valencia,
- Bangkok,
- Edinburgh, Lothian
- Brighton, Sussex
- Coventry, Warwickshire
- London,
- London,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HIVA Phase 2 Study Of PF-00232798 In HIV Positive Patients
NCT00495677
- Frankfurt am Main,
- Koeln,
Male
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information | ||||
---|---|---|---|---|
Brief Title | A Compassionate Access Protocol For Those Patients Who Have Completed A4001029 | |||
Brief Summary | This is a compassionate study to provide continued access to maraviroc for only those subjects completing study A4001029 who are showing clinical benefit. Assessments of safety and tolerability of maraviroc when added to OBT will be continued. | |||
Detailed Description | Not Provided | |||
Study Type | Expanded Access | |||
Intervention | Drug: Maraviroc
150 mg twice per day Other Name: Celsentri | |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Expanded Access Status | No longer available | |||
Contacts | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries | Canada | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number | NCT00801515 | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor | ViiV Healthcare | |||
Collaborators | Pfizer | |||
Investigators |
| |||
PRS Account | ViiV Healthcare | |||
Verification Date | July 2011 |